Wat is de prijs voor Abivax S.A. (ABVX)

Het prijs van Abivax S.A. (ABVX) is $121.34

Wat is de marktkapitalisatie voor Abivax S.A. (ABVX)

Marktkapitalisatie voorAbivax S.A. (ABVX) is $10.58B

Abivax S.A. (ABVX) Winst

Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX464, is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's disease, and COVID-19, and is in Phase IIa trials for rheumatoid arthritis. This compound has also successfully completed a Phase IIa study focused on achieving viral remission in HIV patients. Additionally, the company is advancing ABX 196, an immune-enhancing agent, through Phase 1/2 clinical trials for hepatocellular cancer. Beyond these main programs, Abivax is also engaged in research initiatives targeting Dengue fever, influenza, and the respiratory syncytial virus. The company holds significant licensing agreements with esteemed institutions such as the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie.

Jaar	Winst	Wijzigen
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Winst

Wijzigen

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Winst	Winstverschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Moderna, Inc. MRNA.US	$-3.09B	-	US
CSL Limited CSL.AX	$-4.02B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Bedrijf

Winst

Winstverschil

Land

Vertex Pharmaceuticals Incorporated

VRTX.US

$5.27B

Argenx SE

ARGX.US

$1.95B

Moderna, Inc.

MRNA.US

$-3.09B

CSL Limited

CSL.AX

$-4.02B

Lonza Group AG

LONN.SW

Abivax S.A.

ABVX

Categorie